Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00401
|
|||||
| Drug Name |
Talinolol
|
|||||
| Synonyms |
(+-)-N-Cyclohexyl-N'-(4-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)phenyl)urea; (+-)-Talinolol; 1-(3-(3-Cyclohexylureido)phenoxy)-3-(tert-butylamino)-2-propanol; 1-(4-(3-(TERT-BUTYLAMINO)-2-HYDROXYPROPOXY)PHENYL)-3-CYCLOHEXYLUREA; 1-(4-(cyclohexylureido)phenoxy)-3-(tert-butylamino)-2-propanol; 1-(4-Cyclohexylureidophenoxy)-2-hydroxy-3-tert-butylaminopropane; 38649-73-9; Cordanum; NCGC00164542-01; Racemic talinolol; Talinolol (INN); Talinolol [INN]; Talinololum [INN-Latin]
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Gastrointestinal motility disorder [ICD11: DE2Z] | Phase 1 | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C20H33N3O3
|
|||||
| Canonical SMILES |
CC(C)(C)NCC(COC1=CC=C(C=C1)NC(=O)NC2CCCCC2)O
|
|||||
| InChI |
InChI=1S/C20H33N3O3/c1-20(2,3)21-13-17(24)14-26-18-11-9-16(10-12-18)23-19(25)22-15-7-5-4-6-8-15/h9-12,15,17,21,24H,4-8,13-14H2,1-3H3,(H2,22,23,25)
|
|||||
| InChIKey |
MXFWWQICDIZSOA-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 57460-41-0
|
|||||
| Pharmaceutical Properties | Molecular Weight | 363.5 | Topological Polar Surface Area | 82.6 | ||
| Heavy Atom Count | 26 | Rotatable Bond Count | 8 | |||
| Hydrogen Bond Donor Count | 4 | Hydrogen Bond Acceptor Count | 4 | |||
| XLogP |
2.6
|
|||||
| PubChem CID | ||||||
| PubChem SID |
103096738
, 103401016
, 104343015
, 107929351
, 117537352
, 124580994
, 125712702
, 126580194
, 126725781
, 126737449
, 127339737
, 127339738
, 127339739
, 131492773
, 135027207
, 135066580
, 135555209
, 135653641
, 135707467
, 135888304
, 136895027
, 137114987
, 142640331
, 144205724
, 14926104
, 162057748
, 162118068
, 162848586
, 164765202
, 165745358
, 170466514
, 170558731
, 178101379
, 179323274
, 184547412
, 202554924
, 215742084
, 226457382
, 252091637
, 252492541
, 26757961
, 43125295
, 50060575
, 50068853
, 51091522
, 57317059
, 77170990
, 8192333
, 95612779
, 98940985
|
|||||
| ChEBI ID |
CHEBI:135533
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | MRP2 | Transporter Info | Multidrug resistance-associated protein 2 | Substrate | [2] | |
| OATP1A2 | Transporter Info | Organic anion transporting polypeptide 1A2 | Substrate | [3] | ||
| OATP2B1 | Transporter Info | Organic anion transporting polypeptide 2B1 | Substrate | [4] | ||
| P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [5] | ||
| References | ||||||
| 1 | ClinicalTrials.gov (NCT01635608) Absorption of Paracetamol, Talinolol and Amoxicillin After Oral Administration Using Non-caloric and Caloric Water | |||||
| 2 | FDA Drug Development and Drug Interactions | |||||
| 3 | Concentration-dependent effect of naringin on intestinal absorption of beta(1)-adrenoceptor antagonist talinolol mediated by p-glycoprotein and organic anion transporting polypeptide (Oatp). Pharm Res. 2009 Mar;26(3):560-7. | |||||
| 4 | Species difference in the effect of grapefruit juice on intestinal absorption of talinolol between human and rat. J Pharmacol Exp Ther. 2010 Jan;332(1):181-9. | |||||
| 5 | Grapefruit juice-drug interactions: Grapefruit juice and its components inhibit P-glycoprotein (ABCB1) mediated transport of talinolol in Caco-2 cells. J Pharm Sci. 2007 Oct;96(10):2808-17. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.